novo nordisk's semaglutide failed to slow alzheimer's disease progression reports 2 trial failures for GLP-1 in Major Novo Nordisk trial finds
Description
Management: Generally safe
Stop the medication immediately and seek emergency medical care if these symptoms occur
The risk-benefit math does not support that
Related Blog Posts:
It also allows patients to sign-up for email alerts to be notified when a GLP-1 supply becomes available in their area, and when the status of a GLP-1 drug is updated on the FDA's Drug Shortage List
